Topline results from the pivotal phase II EMPOWER-CSCC 1 study showed that the PD-1 inhibitor cemiplimab (REGN2810) induced an overall response rate (ORR) of 46.3% in patients with advanced cutaneous squamous cell carcinoma (CSCC).
at the 2017 ASH Annual Meeting demonstrating activity with cemiplimab in patients with B-lymphoid malignancies.
- Papadopoulos KP, Owonikoko TK, Johnson ML, et al. REGN2810: A fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study. J Clin Oncol 35, 2017 (suppl; abstr 9503).
... to read the full story